1. Introduction {#sec1-molecules-23-01099}
===============

The methylation of lysine residues on histones is involved in the epigenetic control of gene expression associated with not only many cellular events but also several diseases \[[@B1-molecules-23-01099]\]. Histone methylation and demethylation reactions are catalyzed by a series of histone lysine methyltransferases (HKMTs) and histone lysine demethylases (KDMs), respectively \[[@B1-molecules-23-01099]\]. Thus, the methylation is reversibly regulated by both HKMTs and KDMs.

Lysine-specific demethylase 1 (LSD1), which is one of the KDMs and a flavin adenine dinucleotide (FAD)-dependent oxidase, catalytically removes the methyl groups of mono- or di-methylated lysine residues at the fourth position of histone H3 (H3K4me1/me2) \[[@B2-molecules-23-01099]\]. In prostate cancer cells, LSD1 acquires H3K9me1/me2 demethylation activity by interacting with an androgen receptor \[[@B3-molecules-23-01099]\]. In addition, LSD1 demethylates methyl groups of mono- or di-methylated lysine residues of non-histone proteins (e.g., p53, DNMT, and E2F1) to regulate their activities and functions \[[@B4-molecules-23-01099],[@B5-molecules-23-01099],[@B6-molecules-23-01099]\]. LSD1 forms a co-repression complex with CoREST, recruiting other transcription factors, such as HDAC1, Gfi-1b, TLX, KHMTs, and other KDMs \[[@B7-molecules-23-01099],[@B8-molecules-23-01099],[@B9-molecules-23-01099],[@B10-molecules-23-01099],[@B11-molecules-23-01099]\], to epigenetically regulate the expression of the genes associated with several diseases, such as cancer, globin disorders, and viral infections \[[@B12-molecules-23-01099],[@B13-molecules-23-01099],[@B14-molecules-23-01099]\]. Therefore, LSD1 is interesting as a molecular target for the therapy of diseases. To date, a number of LSD1 inactivators have been developed \[[@B15-molecules-23-01099],[@B16-molecules-23-01099],[@B17-molecules-23-01099]\] and some of them are being evaluated in clinical trials for cancer \[[@B18-molecules-23-01099],[@B19-molecules-23-01099]\].

We have reported several peptide- or small molecule-based LSD1 inactivators so far \[[@B20-molecules-23-01099],[@B21-molecules-23-01099],[@B22-molecules-23-01099],[@B23-molecules-23-01099],[@B24-molecules-23-01099],[@B25-molecules-23-01099],[@B26-molecules-23-01099],[@B27-molecules-23-01099],[@B28-molecules-23-01099],[@B29-molecules-23-01099]\]. For instance, PCPA-Lys-4 H3-21, a peptide-based LSD1 inactivator \[[@B22-molecules-23-01099]\] ([Figure 1](#molecules-23-01099-f001){ref-type="fig"}), drops off *trans*-2-phenylcyclopropylamine (PCPA), a pharmacophore for LSD1 inactivation \[[@B30-molecules-23-01099],[@B31-molecules-23-01099]\], in the active pocket of LSD1 to inactivate LSD1 potently and selectively. Further, we identified NCD38, a potent and selective small molecule LSD1 inhibitor \[[@B22-molecules-23-01099]\] ([Figure 1](#molecules-23-01099-f001){ref-type="fig"}) that showed sufficient bioactivity in in vivo studies \[[@B32-molecules-23-01099],[@B33-molecules-23-01099]\]. Following these findings, we considered that it is possible to improve the LSD1 inhibitory activities of peptide- or small molecule-based LSD1 inactivators. In particular, a novel design of peptide-based LSD1 inactivators could lead to high specificity toward LSD1 and their off-target effects could be limited as compared with small molecule inhibitors. Thus, peptide-based LSD1 inactivators could exhibit high therapeutic potential toward LSD1-associated diseases \[[@B12-molecules-23-01099],[@B13-molecules-23-01099],[@B14-molecules-23-01099]\].

In 2007, Cole, Yu, and co-workers reported a co-crystal structure of LSD1 with a histone H3-based suicide substrate incorporating *N*-methylpropargylamine, and revealed that the substrate reacted with FAD to form three consecutive γ-turn structures in the active pocket of LSD1 ([Figure 2](#molecules-23-01099-f002){ref-type="fig"}) \[[@B34-molecules-23-01099]\]. The unique secondary structures could contribute to the substrate specificity toward LSD1 \[[@B34-molecules-23-01099]\]. Based on that report, we envisioned that the LSD1 inhibitory activities of peptide-based inactivators would be improved by regulating their secondary structures. Thus, peptides that easily form three consecutive γ-turn structures should exhibit strong LSD1 inhibitory activity and high selectivity. Herein we report novel histone H3 peptide-based LSD1 inactivators incorporating α,α-disubstituted amino acids that work as γ-turn inducers.

2. Results {#sec2-molecules-23-01099}
==========

2.1. Design {#sec2dot1-molecules-23-01099}
-----------

Previously, it was reported that α,α-disubstituted amino acids predominantly induced the formation of γ-turn structures \[[@B35-molecules-23-01099]\]. Thus, we hypothesized that the introduction of α,α-disubstituted amino acids into the sequence of a histone H3-based peptide would stabilize the formation of three consecutive γ-turn structures in the active pocket of LSD1. To verify the hypothesis, we selected LSD1 inactivator **1** as the model and reference peptide ([Figure 3](#molecules-23-01099-f003){ref-type="fig"}), because peptide **1** has both a concise sequence and appropriate LSD1 inhibitory activity \[[@B28-molecules-23-01099]\]. We designed histone H3 peptide-based LSD1 inactivators **2a**--**c** by incorporating two of the following α,α-disubstituted amino acids: 2-aminoisobutyric acid (Aib) (**2a**), 1-aminocyclohexanecarboxylic acid (Acc) (**2b**), and 2-aminoadamantane-2-carboxylic acid (Aadc) (**2c**), one on each side of the lysine residue bearing a PCPA moiety ([Figure 3](#molecules-23-01099-f003){ref-type="fig"}).

2.2. Synthesis {#sec2dot2-molecules-23-01099}
--------------

The synthesis of H3-11 peptide analogs **2** is shown in [Scheme 1](#molecules-23-01099-sch001){ref-type="scheme"}. Peptides **2** were synthesized by Fmoc-based solid-phase peptide synthesis (SPPS) according to modified previous procedures for histone H3-based peptides \[[@B22-molecules-23-01099],[@B25-molecules-23-01099],[@B28-molecules-23-01099]\]. Initially, we prepared peptides **3** incorporating the α,α-disubstituted amino acids by Fmoc-based SPPS. Next, peptides **3** were converted into mesylates **4** with mesyl chloride (MsCl), and then the mesyl groups of **4** were substituted with PCPA to obtain desired precursors **5**. Precursors **5** were cleaved from the resin and purified by high-performance liquid chromatography (HPLC) followed by lyophilization and identification by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to obtain the desired peptides **2** as a white powder.

2.3. In Vitro Evaluation of LSD1 Inhibitory Activity {#sec2dot3-molecules-23-01099}
----------------------------------------------------

We assayed for the LSD1 inhibitory activities of novel peptides **2a**--**c**. The assay was performed with an LSD1 Fluorometric Drug Discovery Kit (Enzo Life Sciences, New York, NY, USA, BML-AK544-0001). The results are summarized in [Table 1](#molecules-23-01099-t001){ref-type="table"}. Control peptide **1** inactivated LSD1 potently compared to PCPA. As expected, the LSD1 inhibitory activities of novel peptides **2a**--**c** were higher than that of **1**. In particular, peptide **2b** was the most potent LSD1 inactivator among the peptides tested in this study. Next, we examined the time-dependency of LSD1 inhibition by peptides **2a**--**c**. As shown in [Supplementary Figure S1](#app1-molecules-23-01099){ref-type="app"}, peptide **2a**--**c** inhibited LSD1 enzyme activities in a time-dependent manner, which indicates that peptides **2a**--**c** inactivate LSD1 irreversibly. We also assayed for the inhibitory activities of monoamine oxidases (MAOs), which are FAD-dependent oxidases associated with neurotransmitter metabolism \[[@B36-molecules-23-01099]\], to investigate the selectivity toward LSD1. For this investigation, we used a MAO-Glo^TM^ Assay System (Promega, Madison, WI, USA, V1401). As shown in [Table 1](#molecules-23-01099-t001){ref-type="table"}, all peptides did not inactivate MAO-A or MAO-B at the concentration of 10 µM, whereas PCPA, the positive control, inactivated both MAO-A and MAO-B. Furthermore, we tested the inhibitory activities of peptides **2a**--**c** for KDM4C, an isoform of α-ketoglutarate/Fe(II)-dependent KDMs \[[@B37-molecules-23-01099]\]. As a result, peptides **2a**--**c** hardly inhibited KDM4C activities at a concentration of 10 μM ([Supplementary Figure S2](#app1-molecules-23-01099){ref-type="app"}). Thus, the novel peptides **2a**--**c** were found to be irreversible LSD1-selective inactivators.

3. Discussion {#sec3-molecules-23-01099}
=============

In this work, we designed and synthesized γ-turn-inducing novel peptides **2a**--**c** incorporating α,α-disubstituted amino acids and evaluated them in an in vitro LSD1 inhibitory assay. We revealed that peptides **2a**--**c** were potent and selective LSD1 inactivators compared to reference peptide **1**. In particular, peptide **2b** incorporating one Acc each on both sides of the lysine residue bearing the PCPA moiety showed the most potent LSD1 inhibitory activity and the highest LSD1 selectivity (\>170-fold).

Based on these results and our previous findings \[[@B22-molecules-23-01099],[@B25-molecules-23-01099],[@B28-molecules-23-01099]\], we consider that peptides **2a**--**c** incorporating α,α-disubstituted amino acids as γ-turn inducers, particularly **2b**, form three consecutive γ-turn structures in the active pocket of LSD1 to be highly recognized by LSD1 and thereby strongly inactivating LSD1 ([Figure 4](#molecules-23-01099-f004){ref-type="fig"}). Indeed, our docking study using a short model peptide based on **2b** suggested that it forms three consecutive γ-turn structures and binds to the active pocket of LSD1 ([Supplementary Figure S3](#app1-molecules-23-01099){ref-type="app"}). Although we have not obtained any experimental results regarding the secondary structures of the peptides incorporating α,α-disubstituted amino acids in the active pocket of LSD1, structural investigation using various approaches, such as NMR analysis and computational chemistry, is underway.

The structures of peptides are often a source of problems, such as low membrane permeability or low tolerance to proteases, but those problems could be solved by introducing drug delivery systems \[[@B38-molecules-23-01099]\]. Meanwhile, it was reported that more hydrophobic histone H3-based cyclic peptides penetrate the cell membrane to exert an antiproliferative effect on cancer cells by inhibiting LSD1 in the cells, but less hydrophobic non-cyclic ones do not \[[@B39-molecules-23-01099],[@B40-molecules-23-01099]\]. Recently, it was also reported that a more hydrophobic H3-based cyclic peptide stabilized by a disulfide bridge penetrates the cell membrane and inhibits LSD1, thereby inducing histone methylation, whereas a less hydrophobic non-cyclic one does not \[[@B41-molecules-23-01099]\]. Thus, we speculate that our peptides incorporating α,α-disubstituted amino acids might passively penetrate the cell membrane to regulate LSD1 cellular function, because the peptides have hydrophobic properties and secondary structures stabilized by γ-turn inducers. In addition, it was reported that the introduction of unnatural amino acids into the original peptide sequence could improve the tolerance to protease \[[@B39-molecules-23-01099],[@B42-molecules-23-01099]\]. Thus, we also expect that our peptides would exhibit protease tolerance. In the future, we are going to test the cellular activities of our peptides.

4. Materials and Methods {#sec4-molecules-23-01099}
========================

4.1. General Methods {#sec4dot1-molecules-23-01099}
--------------------

All reagents were purchased and used as received. Fmoc-Aib-OH and Fmoc-Acc-OH were purchased from Watanabe Chemical Industries (Hiroshima, Japan). Fmoc-Aadc-OH was prepared from H-Aadc-OH (Ark Pharm, Arlington Heights, IL, USA) via a standard method for Fmoc introduction \[[@B43-molecules-23-01099]\]. Obtained peptides were purified by preparative HPLC and the purity was estimated by analytical HPLC. Preparative HPLC was performed with a pump system of JASCO PU-2028 Plus (JASCO , Tokyo, Japan) and a Cosmosil 5C~18~-AR-II column (20 × 250 mm, Nacalai Tesque, Kyoto, Japan) using a linear gradient of 0.1% trifluoroacetic acid (TFA) in CH~3~CN and 0.1% aqueous TFA at the flow rate of 5.0 mL min^−1^, and detection was at 220 nm. Analytical HPLC was carried out with a pump system of JASCO PU-2028 Plus and a Cosmosil 5C~18~-AR-II column (4.6 × 250 mm, Nacalai Tesque) using a linear gradient of 0.1% TFA in CH~3~CN and 0.1% TFA in H~2~O (1.0 mL min^−1^, 220 nm). All peptides were characterized by MALDI-TOF MS using a Bruker Autoflex (Bruker, Billerica, MA, USA) with α-cyano-4-hydroxycinnamic acid (CHCA) as the matrix.

4.2. Synthesis of Peptides with γ-Turn Inducers {#sec4dot2-molecules-23-01099}
-----------------------------------------------

PCPA-Lys-4 peptides were synthesized using a modified strategy based on the published method for PCPA-Lys-4 H3-21 \[[@B22-molecules-23-01099],[@B25-molecules-23-01099],[@B28-molecules-23-01099]\]. The synthesis of the protected mesyl-Lys-4 peptide sequence was accomplished on the resin based on standard Fmoc-based SPPS according to literature \[[@B44-molecules-23-01099],[@B45-molecules-23-01099],[@B46-molecules-23-01099]\] and Boc-Ala-OH was used as the *N*-terminal amino acid. The resin was treated with 5 equivalents of *trans*-2-phenylcyclopropylamine hydrochloride and 10 equivalents of Et~3~N in 1:1 solution of H~2~O/CH~3~CN for 3 days at room temperature. Deprotection and cleavage from the resin were performed with TFA/thioanisole/H~2~O (85:10:5) solution. The desired peptide was collected by preparative RP-HPLC and lyophilized to give a white powder. MALDI-TOF MS (*m*/*z*): Calcd. for PCPA-Lys-4 H3-11 (**1**) (\[M + H\]^+^): 1364.529. Found: 1364.322. Calcd. for Aib peptide (**2a**) (\[M + H\]^+^): 1305.572. Found: 1305.155. Calcd. for Acc peptide (**2b**) (\[M + H\]^+^): 1385.702. Found: 1385.293. Calcd. for Aadc peptide (**2c**) (\[M + H\]^+^): 1489.854. Found: 1489.370.

4.3. Assay for LSD1 Inhibitory Activity {#sec4dot3-molecules-23-01099}
---------------------------------------

Assays for LSD1 inhibitory activity were performed using an LSD1 Fluorometric Drug Discovery Kit (Enzo Life Sciences, BML-AK544-0001). Inhibitors were pre-incubated with LSD1 (0.5 µg/well; room temperature; 15 min) before reactions were initiated by the addition of H3K4me2 peptide (2.3 µg/well, 20 µM) into all wells except the blank. After incubation (room temperature; 30 min), CeLLestial^TM^ Red and HRP in the assay buffer were added and the incubation was prolonged (room temperature; 5 min). The fluorescence of the wells was measured on a 2030 ARVO^TM^ X3 Multilabel Reader (PerkinElmer, Waltham, MA, USA, excitation: 540 nm; detection: 590 nm) and % inhibition was calculated from the fluorescence readings of inhibited wells relative to those of control wells. The concentration of test compounds that resulted in 50% inhibition was determined by plotting log \[Inh\] against the logit function of the % inhibition. IC~50~ values were determined by regression analysis of the concentration/inhibition data.

4.4. Assay for MAO Inhibitory Activity {#sec4dot4-molecules-23-01099}
--------------------------------------

Assays for MAO inhibitory activity were carried out according to the supplier's protocol using a MAO-Glo^TM^ Assay System (Promega, V1401). MAO-A (18 units/mL) or MAO-B (6 units/mL) (Sigma-Aldrich, Saint Louis, MO, USA, 25 µL/well), 160 µM (for MAO-A) or 16 µM (for MAO-B) (4*S*)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid (12.5 µL/well), a MAO substrate, and various concentrations of inhibitors (12.5 µL/well) were incubated at room temperature. Reactions were stopped after 60 min by adding reconstituted Luciferin Detection Reagent (50 µL/well). Then, 20 min after the addition of this reagent, the chemiluminescence of the wells was measured with a 2030 ARVO^TM^ X3 Multilabel Reader (PerkinElmer). For data processing, the same procedure as that for LSD1 inhibitory activity was used.

5. Conclusions {#sec5-molecules-23-01099}
==============

In summary, we described the design, synthesis, and in vitro evaluation of the LSD1 inhibitory activities of novel histone H3 peptide-based LSD1 inactivators **2a**--**c** incorporating α,α-disubstituted amino acids as γ-turn inducers. We revealed that the peptides **2a**--**c** were potent and selective LSD1 inactivators compared to reference peptide **1**. In particular, peptide **2b** incorporating one Acc on each side of lysine residue bearing a PCPA moiety was the most potent and selective LSD1 inactivator. These findings are useful for the further development of histone H3 peptide-based LSD1 inactivators. Detailed studies of peptides incorporating γ-turn inducers are underway in our laboratory.
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![Structures of *trans*-2-phenylcyclopropylamine (PCPA) and its analogs as LSD1 inactivators.](molecules-23-01099-g001){#molecules-23-01099-f001}

![Secondary structure of a histone H3-based suicide substrate in the active pocket of LSD1 (PDB: 2UXN). (**A**) View of the secondary structure of the histone H3-based suicide substrate in the active pocket of LSD1. Intramolecular hydrogen bonds are indicated by the white dotted line and their lengths are shown in italics. (**B**) Schematic diagram of the secondary structure of the histone H3-based suicide substrate in the active pocket of LSD1. Intramolecular hydrogen bonds are indicated by the red line and their lengths are shown in italics.](molecules-23-01099-g002){#molecules-23-01099-f002}

![Structure of PCPA-Lys 4 H3-11 (**1**) (**left**). Design of novel histone H3 peptide-based LSD1 inactivators **2a**--**c** incorporating α,α-disubstituted amino acids that work as γ-turn inducers (**right**).](molecules-23-01099-g003){#molecules-23-01099-f003}

![Preparation of novel histone H3 peptide-based LSD1 inactivators **2a**--**c** with γ-turn inducers by Fmoc-based SPPS (Boc-Ala-OH was used as the *N*-terminal amino acid). Reagents and conditions: (**a**) MsCl, Et~3~N in THF; (**b**) PCPA, Et~3~N in H~2~O:CH~3~CN solution; (**c**) TFA, thioanisole, H~2~O; and (**d**) preparative HPLC. Peptide chains shown in italics are protected.](molecules-23-01099-sch001){#molecules-23-01099-sch001}

![A proposed secondary structure of histone H3 peptide-based LSD1 inactivator **2b** in the active pocket of LSD1 is shown in a schematic diagram. Intramolecular hydrogen bonds are indicated in red.](molecules-23-01099-g004){#molecules-23-01099-f004}

molecules-23-01099-t001_Table 1

###### 

LSD1 and MAO inhibitory activities of peptides **2a**--**c**.

  Compound   IC~50~ (µM) ^1^                 
  ---------- ----------------- ------------- -------------
  PCPA       16.5 ± 1.9        6.00 ± 1.38   6.54 ± 0.51
  **1**      0.126 ± 0.002     \>10          \>10
  **2a**     0.0891 ± 0.0053   \>10          \>10
  **2b**     0.0584 ± 0.0025   \>10          \>10
  **2c**     0.0724 ± 0.0040   \>10          \>10

^1^ Values are means ± S.D. of at least three experiments.
